Decolonization in prevention of health care-associated infections

Clinical Microbiology Reviews

Volumn 29, Issue 2, 2016, Pages 201-221

  Septimus, Edward J ^a,b   Schweizer, Marin L ^c,d,e  

^a HOSPITAL CORPORATION OF AMERICA   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIINFECTIVE AGENT; BACITRACIN; CHLORHEXIDINE GLUCONATE; HEXACHLOROPHENE; HYPOCHLORITE SODIUM; LYSOSTAPHIN; OMIGANAN; POVIDONE IODINE; PSEUDOMONIC ACID; RETAPAMULIN; TEA TREE OIL; TRICLOSAN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; ECONOMIC ASPECT; HEALTHCARE ASSOCIATED INFECTION; HUMAN; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MICROBIAL COLONIZATION; MOUTH HYGIENE; NEUROTOXICITY; NONHUMAN; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DEFECT; SURGICAL INFECTION; WASTE MANAGEMENT; WOUND; BACTERIUM; CROSS INFECTION; DRUG EFFECTS; FUNGUS; GASTROINTESTINAL TRACT; MICROBIOLOGY; NOSE; SKIN; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; BACTERIA; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FUNGI; GASTROINTESTINAL TRACT; HUMANS; NOSE; SKIN;

EID: 84956773073     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00049-15     Document Type: Article

References (176)

1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed 7 May 2015.
2. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK. 2014. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370:1198-1208. http://dx.doi.org/10.1056/NEJMoa1306801.
3. Stone PW. 2009. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res 9:417-422. http://dx.doi.org/10.1586/erp.09.53.
4. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, Keohane C, Denham CR, Bates DW. 2013. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 173:2039 -2046. http://dx.doi.org/10.1001/jamainternmed.2013.9763.
5. Scott RD. 2009. The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention. http://www.cdc.gov/HAI/pdfs/hai/Scott_CostPaper.pdf. Accessed 27 August 2015
6. Umscheid CA, Mitchell MD, Doshi JA, Agarwal R, Williams K, Brennan PJ. 2011. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect Control Hosp Epidemiol 32:101-114. http://dx.doi.org/10.1086 /657912.
7. U.S. Department of Health and Human Services. 16 July 2014, posting date. National action plan to prevent health care-associated infections: road map to elimination. http://www.health.gov/hai/prevent_hai.asp #SSI. Accessed 21 May 2015.
8. Centers for Medicare and Medicaid Services. 2015. Medicare.gov HospitalCompare. Accessed 21 May 2015.
9. Lebreton F, van Schaik W, McGuire AM, Godfrey P, Griggs A, Mazumdar V, Corander J, Cheng L, Saif S, Young S, Zeng Q, Wortman J, Birren B, Willems RJ, Earl AM, Gilmore MS. 2013. Emergence of epidemic multidrug-resistant Enterococcus faecium from animal and commensal strains. mBio 4:e00534-13. http://dx.doi.org/10.1128/mBio00534-13.
10. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL. 2005. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5:751-762. http://dx.doi.org /10.1016/S1473-3099(05)70295-4.
11. Oostdijk EA, de Smet AM, Blok HE, Thieme Groen ES, van Asselt GJ, Benus RF, Bernards SA, Frenay IH, Jansz AR, de Jongh BM, Kaan JA, Leverstein-van Hall MA, Mascini EM, Pauw W, Sturm PD, Thijsen SF, Kluytmans JA, Bonten MJ. 2010. Ecological effects of selective decontamination on resistant gram-negative bacterial colonization. Am J Respir Crit Care Med 181:452-457. http://dx.doi.org/10.1164/rccm.200908-1210OC.
12. Liberati A, D’Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E. 2009. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev 2009: CD000022. http://dx.doi.org/10.1002/14651858.CD000022.pub3.
13. Buffie CG, Pamer EG. 2013. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 13:790-801. http: //dx.doi.org/10.1038/nri3535.
14. VandenBergh MF, Yzerman EP, van Belkum A, Boelens HA, Sijmons M, Verbrugh HA. 1999. Follow-up of Staphylococcus aureus nasal carriage after 8 years: redefining the persistent carrier state. J Clin Microbiol 37:3133-3140.
15. den Heijer CD, van Bijnen EM, Paget WJ, Pringle M, Goossens H, Bruggeman CA, Schellevis FG, Stobberingh EE. 2013. Prevalence and resistance of commensal Staphylococcus aureus, including meticillin-resistant S aureus, in nine European countries: a cross-sectional study. Lancet Infect Dis 13:409-415. http://dx.doi.org/10.1016/S1473-3099 (13)70036-7.
16. Graham PL, III, Lin SX, Larson EL. 2006. A U.S. population-based survey of Staphylococcus aureus colonization. Ann Intern Med 144:318-325. http://dx.doi.org/10.7326/0003-4819-144-5-200603070-00006.
17. Charlebois ED, Bangsberg DR, Moss NJ, Moore MR, Moss AR, Chambers HF, Perdreau-Remington F. 2002. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis 34:425-433. http://dx.doi.org/10.1086/338069.
18. Williams V, Simor AE, Kiss A, McGeer A, Hirji Z, Larios OE, Moore C, Weiss K. 2015. Is the prevalence of antibiotic-resistant organisms changing in Canadian hospitals? Comparison of point-prevalence survey results in 2010 and 2012. Clin Microbiol Infect 21:553-559. http://dx.doi.org/10.1016/j.cmi.2015.01.024.
19. Sim BL, McBryde E, Street AC, Marshall C. 2013. Multiple site surveillance cultures as a predictor of methicillin-resistant Staphylococcus aureus infections. Infect Control Hosp Epidemiol 34:818-824. http://dx.doi.org/10.1086/671273.
20. Peters PJ, Brooks JT, McAllister SK, Limbago B, Lowery HK, Fosheim G, Guest JL, Gorwitz RJ, Bethea M, Hageman J, Mindley R, McDougal LK, Rimland D. 2013. Methicillin-resistant Staphylococcus aureus colonization of the groin and risk for clinical infection among HIV-infected adults. Emerg Infect Dis 19:623-629. http://dx.doi.org/10.3201/eid1904.121353.
21. Szumowski JD, Wener KM, Gold HS, Wong M, Venkataraman L, Runde CA, Cohen DE, Mayer KH, Wright SB. 2009. Methicillin-resistant Staphylococcus aureus colonization, behavioral risk factors, and skin and soft-tissue infection at an ambulatory clinic serving a large population of HIV-infected men who have sex with men. Clin Infect Dis 49:118-121. http://dx.doi.org/10.1086/599608.
22. Russell DL, Flood A, Zaroda TE, Acosta C, Riley MM, Busuttil RW, Pegues DA. 2008. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant 8:1737-1743. http://dx.doi.org/10.1111/j.1600-6143.2008.02304.x.
23. Montecalvo MA, Shay DK, Gedris C, Petrullo C, Uman J, Rodney K, Jarvis WR, Wormser GP. 1997. A semiquantitative analysis of the fecal flora of patients with vancomycin-resistant enterococci: colonized patients pose an infection control risk. Clin Infect Dis 25:929-930. http: //dx.doi.org/10.1086/597643.
24. Montecalvo MA, Shay DK, Patel P, Tacsa L, Maloney SA, Jarvis WR, Wormser GP. 1996. Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med 156:1458-1462.
25. Uckay I, Hoffmeyer P, Lew D, Pittet D. 2013. Prevention of surgical site infections in orthopaedic surgery and bone trauma: state-of-the-art update. J Hosp Infect 84:5-12. http://dx.doi.org/10.1016/j.jhin.2012.12.014.
26. Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt LA, Weinstein RA, Sepkowitz KA, Jernigan JA, Sanogo K, Wong ES. 2013. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 368:533-542. http://dx.doi.org/10.1056/NEJMoa1113849.
27. Wenzel RP, Edmond MB. 2010. Infection control: the case for horizontal rather than vertical interventional programs. Int J Infect Dis 14(Suppl 4):S3-S5. http://dx.doi.org/10.1016/j.ijid.2010.05.002.
28. Septimus E, Weinstein RA, Perl TM, Goldmann DA, Yokoe DS. 2014. Approaches for preventing healthcare-associated infections: go long or go wide? Infect Control Hosp Epidemiol 35(Suppl 2):S10-S14. http://dx.doi.org/10.1086/677827.
29. Septimus EJ, Hayden MK, Kleinman K, Avery TR, Moody J, Weinstein RA, Hickok J, Lankiewicz J, Gombosev A, Haffenreffer K, Kaganov RE, Jernigan JA, Perlin JB, Platt R, Huang SS. 2014. Does chlorhexidine bathing in adult intensive care units reduce blood culture contamination? A pragmatic cluster-randomized trial. Infect Control Hosp Epidemiol 35(Suppl 3):S17-S22. http://dx.doi.org/10.1086/677822.
30. Harris AD, Nemoy L, Johnson JA, Martin-Carnahan A, Smith DL, Standiford H, Perencevich EN. 2004. Co-carriage rates of vancomycin-resistant Enterococcus and extended-spectrum beta-lactamase- producing bacteria among a cohort of intensive care unit patients: implications for an active surveillance program. Infect Control Hosp Epidemiol 25:105-108. http://dx.doi.org/10.1086/502358.
31. Mody L, Gibson KE, Horcher A, Prenovost K, McNamara SE, Foxman B, Kaye KS, Bradley S. 2015. Prevalence of and risk factors for multi- drug-resistant Acinetobacter baumannii colonization among high-risk nursing home residents. Infect Control Hosp Epidemiol 36:1155-1162. http://dx.doi.org/10.1017/ice.2015.143.
32. Furuno JP, Perencevich EN, Johnson JA, Wright MO, McGregor JC, Morris JG, Jr, Strauss SM, Roghman MC, Nemoy LL, Standiford HC, Hebden JN, Harris AD. 2005. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci co-colonization. Emerg Infect Dis 11:1539-1544. http://dx.doi.org/10.3201/eid1110.050508.
33. Verhoeven PO, Gagnaire J, Botelho-Nevers E, Grattard F, Carricajo A, Lucht F, Pozzetto B, Berthelot P. 2014. Detection and clinical relevance of Staphylococcus aureus nasal carriage: an update. Expert Rev Anti Infect Ther 12:75-89. http://dx.doi.org/10.1586/14787210.2014.859985.
34. Kluytmans J, van Belkum A, Verbrugh H. 1997. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 10:505-520.
35. Nouwen JL, Fieren MW, Snijders S, Verbrugh HA, van Belkum A. 2005. Persistent (not intermittent) nasal carriage of Staphylococcus aureus is the determinant of CPD-related infections. Kidney Int 67:1084-1092. http://dx.doi.org/10.1111/j.1523-1755.2005.00174.x.
36. van Belkum A, Verkaik NJ, de Vogel CP, Boelens HA, Verveer J, Nouwen JL, Verbrugh HA, Wertheim HF. 2009. Reclassification of Staphylococcus aureus nasal carriage types. J Infect Dis 199:1820-1826. http://dx.doi.org/10.1086/599119.
37. Ridenour G, Lampen R, Federspiel J, Kritchevsky S, Wong E, Climo M. 2007. Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillin-resistant Staphylococcus aureus colonization and infection among intensive care unit patients. Infect Control Hosp Epidemiol 28:1155-1161. http://dx.doi.org/10.1086/520102.
38. Schweizer M, Perencevich E, McDanel J, Carson J, Formanek M, Hafner J, Braun B, Herwaldt L. 2013. Effectiveness of a bundled intervention of decolonization and prophylaxis to decrease Gram positive surgical site infections after cardiac or orthopedic surgery: systematic review and meta-analysis. BMJ 346:f2743. http://dx.doi.org/10.1136/bmj.f2743.
39. Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D’Agata EM. 2003. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis 37:1629-1638. http://dx.doi.org/10.1086/379715.
40. Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, Lankiewicz J, Gombosev A, Terpstra L, Hartford F, Hayden MK, Jernigan JA, Weinstein RA, Fraser VJ, Haffenreffer K, Cui E, Kaganov RE, Lolans K, Perlin JB, Platt R. 2013. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 368:2255-2265. http://dx.doi.org/10.1056/NEJMoa1207290.
41. van Rijen MM, Bonten M, Wenzel RP, Kluytmans JA. 2008. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systematic review. J Antimicrob Chemother 61:254-261. http://dx.doi.org/10.1093/jac/dkm480.
42. Kallen AJ, Wilson CT, Larson RJ. 2005. Perioperative intranasal mupirocin for the prevention of surgical-site infections: systematic review of the literature and meta-analysis. Infect Control Hosp Epidemiol 26:916-922. http://dx.doi.org/10.1086/505453.
43. Mody L, Kauffman CA, McNeil SA, Galecki AT, Bradley SF. 2003. Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, place-bo-controlled trial. Clin Infect Dis 37:1467-1474. http://dx.doi.org/10.1086/379325.
44. Nair R, Perencevich EN, Blevins AE, Goto M, Nelson RE, Schweizer ML. 16 June 2015. Clinical effectiveness of mupirocin for preventing Staphylococcus aureus infections in non-surgical settings: a meta-analysis. Clin Infect Dis http://dx.doi.org/10.1186/2047-2994-4-S1-O5.
45. Kalmeijer MD, van Nieuwland-Bollen E, Bogaers-Hofman D, de Baere GA. 2000. Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery. Infect Control Hosp Epidemiol 21:319-323. http://dx.doi.org/10.1086/501763.
46. Nouwen JL, Ott A, Kluytmans-Vandenbergh MF, Boelens HA, Hofman A, van Belkum A, Verbrugh HA. 2004. Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a “culture rule.” Clin Infect Dis 39:806-811.
47. Mermel LA, Eells SJ, Acharya MK, Cartony JM, Dacus D, Fadem S, Gay EA, Gordon S, Lonks JR, Perl TM, McDougal LK, McGowan JE, Maxey G, Morse D, Tenover FC. 2010. Quantitative analysis and molecular fingerprinting of methicillin-resistant Staphylococcus aureus nasal colonization in different patient populations: a prospective, multicenter study. Infect Control Hosp Epidemiol 31:592-597. http://dx.doi.org/10.1086/652778.
48. Cheng VC, Li IW, Wu AK, Tang BS, Ng KH, To KK, Tse H, Que TL, Ho PL, Yuen KY. 2008. Effect of antibiotics on the bacterial load of meticillin-resistant Staphylococcus aureus colonisation in anterior nares. J Hosp Infect 70:27-34. http://dx.doi.org/10.1016/j.jhin.2008.05.019.
49. Mermel LA, Cartony JM, Covington P, Maxey G, Morse D. 2011. Methicillin-resistant Staphylococcus aureus colonization at different body sites: a prospective, quantitative analysis. J Clin Microbiol 49:1119-1121. http://dx.doi.org/10.1128/JCM.02601-10.
50. Lee BY, Wiringa AE, Bailey RR, Goyal V, Lewis GJ, Tsui BY, Smith KJ, Muder RR, 2010. Screening cardiac surgery patients for MRSA: an economic computer model. Am J Managed Care 16:e163-173.
51. Immerman I, Ramos NL, Katz GM, Hutzler LH, Phillips MS, Bosco JA, III. 2012. The persistence of Staphylococcus aureus decolonization after mupirocin and topical chlorhexidine: implications for patients requiring multiple or delayed procedures. J Arthroplasty 27:870-876. http: //dx.doi.org/10.1016/j.arth.2012.01.010.
52. Holton DL, Nicolle LE, Diley D, Bernstein K. 1991. Efficacy of mupirocin nasal ointment in eradicating Staphylococcus aureus nasal carriage in chronic haemodialysis patients. J Hosp Infect 17:133-137. http://dx.doi.org/10.1016/0195-6701(91)90177-A.
53. Loeb MB, Main C, Eady A, Walker-Dilks C. 2003. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 2003:CD003340.
54. Bommer J, Vergetis W, Andrassy K, Hingst V, Borneff M, Huber W. 1995. Elimination of Staphylococcus aureus in hemodialysis patients. ASAIO J 41:127-131. http://dx.doi.org/10.1097/00002480-199501000-00021.
55. Ward A, Campoli-Richards DM. 1986. Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 32:425-444.
56. Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, Pfaller MA, Sheppard D, Twombley J, French PP, Herwaldt LA. 2002. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 346:1871-1877. http://dx.doi.org/10.1056/NEJMoa003069.
57. Ammerlaan HS, Kluytmans JA, Wertheim HF, Nouwen JL, Bonten MJ. 2009. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis 48:922-930. http://dx.doi.org /10.1086/597291.
58. van Rijen M, Bonten M, Wenzel R, Kluytmans J. 2008. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev 2008:CD006216.
59. Ellis MW, Griffith ME, Dooley DP, McLean JC, Jorgensen JH, Patterson JE, Davis KA, Hawley JS, Regules JA, Rivard RG, Gray PJ, Ceremuga JM, Dejoseph MA, Hospenthal DR. 2007. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother 51:3591-3598. http://dx.doi.org/10.1128/AAC.01086-06.
60. Schlett CD, Millar EV, Crawford KB, Cui T, Lanier JB, Tribble DR, Ellis MW. 2014. Prevalence of chlorhexidine-resistant methicillin-resistant Staphylococcus aureus following prolonged exposure. Antimi-crob Agents Chemother 58:4404-4410. http://dx.doi.org/10.1128/AAC.02419-14.
61. Fritz SA, Hogan PG, Hayek G, Eisenstein KA, Rodriguez M, Epplin EK, Garbutt J, Fraser VJ. 2012. Household versus individual approaches to eradication of community-associated Staphylococcus aureus in children: a randomized trial. Clin Infect Dis 54:743-751. http://dx.doi.org /10.1093/cid/cir919.
62. Miller LG, Diep BA. 2008. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 46:752-760. http://dx.doi.org/10.1086/526773.
63. Popovich KJ, Aroutcheva A, Hota B, Beavis KG, Hayden MK, Weinstein RA. 2014. Anatomic sites of colonization with community-associated methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 35:1192-1194. http://dx.doi.org/10.1086/677627.
64. Jones RN, Fritsche TR, Sader HS, Ross JE. 2006. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother 50:2583-2586. http://dx.doi.org/10.1128/AAC.01432-05.
65. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. 2002. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 39:337-341. http://dx.doi.org/10.1053/ajkd.2002.30553.
66. Vasquez JE, Walker ES, Franzus BW, Overbay BK, Reagan DR, Sarubbi FA. 2000. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans’ Affairs hospital. Infect Control Hosp Epidemiol 21:459-464. http://dx.doi.org/10.1086 /501788.
67. Eltringham I. 1997. Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 35:1-8.
68. Patel JB, Gorwitz RJ, Jernigan JA. 2009. Mupirocin resistance. Clin Infect Dis 49:935-941. http://dx.doi.org/10.1086/605495.
69. Udo EE, Jacob LE, Mathew B. 2001. Genetic analysis of methicillin-resistant Staphylococcus aureus expressing high-and low-level mupirocin resistance. J Med Microbiol 50:909-915. http://dx.doi.org/10.1099/0022-1317-50-10-909.
70. Antonio M, McFerran N, Pallen MJ. 2002. Mutations affecting the Rossman fold of isoleucyl-tRNA synthetase are correlated with low-level mupirocin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 46:438-442. http://dx.doi.org/10.1128/AAC.46.2.438-442.2002.
71. Caffrey AR, Quilliam BJ, LaPlante KL. 2010. Risk factors associated with mupirocin resistance in meticillin-resistant Staphylococcus aureus. J Hosp Infect 76:206-210. http://dx.doi.org/10.1016/j.jhin.2010.06.023.
72. Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi FA. 2003. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect Control Hosp Epidemiol 24:342-346. http: //dx.doi.org/10.1086/502218.
73. Annigeri R, Conly J, Vas S, Dedier H, Prakashan KP, Bargman JM, Jassal V, Oreopoulos D. 2001. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Peritoneal Dialysis Int 21:554-559.
74. Upton A, Lang S, Heffernan H. 2003. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother 51:613-617. http://dx.doi.org/10.1093/jac/dkg127.
75. Fawley WN, Parnell P, Hall J, Wilcox MH. 2006. Surveillance for mupirocin resistance following introduction of routine peri-operative prophylaxis with nasal mupirocin. J Hosp Infect 62:327-332. http://dx.doi.org/10.1016/j.jhin.2005.09.022.
76. Poovelikunnel T, Gethin G, Humphreys H. 2015. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. J Antimicrob Chemother 70:2681-2692. http://dx.doi.org/10.1093/jac/dkv169.
77. Soto NE, Vaghjimal A, Stahl-Avicolli A, Protic JR, Lutwick LI, Chapnick EK. 1999. Bacitracin versus mupirocin for Staphylococcus aureus nasal colonization. Infect Control Hosp Epidemiol 20:351-353. http://dx.doi.org/10.1086/501633.
78. Fung S, O’Grady S, Kennedy C, Dedier H, Campbell I, Conly J. 2000. The utility of polysporin ointment in the eradication of methicillin-resistant Staphylococcus aureus colonization: a pilot study. Infect Control Hosp Epidemiol 21:653-655. http://dx.doi.org/10.1086/501709.
79. O’Grady S, Hirji Z, Pejcic-Karapetrovic B, Fung S, Dedier H, Takata-Shewchuk J, Zhang K, Conly J. 2009. A double-blind, randomized, controlled trial of topical polysporin triple compound versus topical mupirocin for the eradication of colonization with methicillin-resistant Staphylococcus aureus in a complex continuing care population. Can J Infect Dis Med Microbiol 20:e49-e55.
80. Gehrig KA, Warshaw EM. 2008. Allergic contact dermatitis to topical antibiotics: Epidemiology, responsible allergens, and management. J Am Acad Dermatol 58:1-21. http://dx.doi.org/10.1016/j.jaad.2007.07.050.
81. Rittenhouse S, Biswas S, Broskey J, McCloskey L, Moore T, Vasey S, West J, Zalacain M, Zonis R, Payne D. 2006. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob Agents Chemother 50:3882-3885. http://dx.doi.org/10.1128/AAC.00178-06.
82. Naderer OJ, Anderson M, Roberts K, Lou Y, Zhu J, Min S, Scangarella Shawar R. 2008. Nasal decolonization of persistent Staphylococcus aureus carriers with twice daily application of retapamulin ointment, 1% for 3 or 5 days, presentation L-1492. 48th ICAAC/46th IDSA Annu Meet, Washington DC.
83. Hill RL, Casewell MW. 2000. The in-vitro activity of povidone-iodine cream against Staphylococcus aureus and its bioavailability in nasal secretions. J Hosp Infect 45:198 -205. http://dx.doi.org/10.1053/jhin.2000.0733.
84. Phillips M, Rosenberg A, Shopsin B, Cuff G, Skeete F, Foti A, Kraemer K, Inglima K, Press R, Bosco J. 2014. Preventing surgical site infections: a randomized, open-label trial of nasal mupirocin ointment and nasal povidone-iodine solution. Infect Control Hosp Epidemiol 35:826-832. http://dx.doi.org/10.1086/676872.
85. Bebko SP, Green DM, Awad SS. 2015. Effect of a preoperative decontamination protocol on surgical site infections in patients undergoing elective orthopedic surgery with hardware implantation. JAMA Surg 150:390-3950. http://dx.doi.org/10.1001/jamasurg.2014.3480.
86. Boyce JM, Pittet D. 2002. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HIPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Am J Infect Control 30:S1-S46.
87. Steed LL, Costello J, Lohia S, Jones T, Spannhake EW, Nguyen S. 2014. Reduction of nasal Staphylococcus aureus carriage in health care professionals by treatment with a nonantibiotic, alcohol-based nasal antiseptic. Am J Infect Control 42:841-846. http://dx.doi.org/10.1016/j.ajic.2014.04.008.
88. Caelli M, Porteous J, Carson CF, Heller R, Riley TV. 2000. Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus. J Hosp Infect 46:236-237.
89. Dryden MS, Dailly S, Crouch M. 2004. A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J Hosp Infect 56:283-286. http://dx.doi.org/10.1016/j.jhin.2004.01.008.
90. Guffey JS, Wilborn J. 2006. Effects of combined 405-nm and 880-nm light on Staphylococcus aureus and Pseudomonas aeruginosa in vitro. Photomed Laser Surg 24:680-683. http://dx.doi.org/10.1089/pho.2006.24.680.
91. Embleton ML, Nair SP, Cookson BD, Wilson M. 2004. Antibody-directed photodynamic therapy of methicillin resistant Staphylococcus aureus. Microb Drug Resist 10:92-97. http://dx.doi.org/10.1089/107662 9041310000.
92. Embleton ML, Nair SP, Cookson BD, Wilson M. 2002. Selective lethal photosensitization of methicillin-resistant Staphylococcus aureus using an IgG-tin (IV) chlorin e6 conjugate. J Antimicrob Chemother 50:857-864. http://dx.doi.org/10.1093/jac/dkf209.
93. Street CN, Pedigo L, Gibbs A, Loebel NG. 2009. Antimicrobial photo-dynamic therapy for the decolonization of methicillin-resistant Staphylococcus aureus from the anterior nares. Proc SPIE 7380:73803B. http: //dx.doi.org/10.1117/12.828279.
94. Bryce E, Wong T, Forrester L, Masri B, Jeske D, Barr K, Errico S, Roscoe D. 2014. Nasal photodisinfection and chlorhexidine wipes decrease surgical site infections: a historical control study and propensity analysis. J Hosp Infect 88:89-95. http://dx.doi.org/10.1016/j.jhin.2014.06.017.
95. Bryce E, Wong T, Roscoe D, Street C, Jeske D, Masri B, Weatherill S, Forrester L. 2012. Nasal decolonization of Staphylococcus aureus with antimicrobial photodynamic therapy. Can J Infect Dis Med Microbiol 23(Suppl B):34B-35B.
96. Bornstein E, Gridley S, Wengender P, Robbins A. 2010. Photodamage to multidrug-resistant gram-positive and gram-negative bacteria by 870 nm/930 nm light potentiates erythromycin, tetracycline and ciprofloxacin. Photochem Photobiol 86:617-627. http://dx.doi.org/10.1111/j.1751-1097.2010.00725.x.
97. Krespi YP, Kizhner V. 2012. Laser-assisted nasal decolonization of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. Am J Otolaryngol 33:572-575. http://dx.doi.org/10.1016/j.amjoto.2012.02.002.
98. Sader HS, Fedler KA, Rennie RP, Stevens S, Jones RN. 2004. Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents Chemother 48:3112-3118. http://dx.doi.org/10.1128/AAC.48.8.3112-3118.2004.
99. Fritsche TR, Rhomberg PR, Sader HS, Jones RN. 2008. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant,-intermediate, and-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 60:399-403. http://dx.doi.org/10.1016/j.diagmicrobio.2007.11.004.
100. von Eiff C, Kokai-Kun JF, Becker K, Peters G. 2003. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood. Antimicrob Agents Chemother 47:3613-3615. http://dx.doi.org/10.1128/AAC.47.11.3613-3615.2003.
101. Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ. 2003. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 47:1589-1597. http://dx.doi.org /10.1128/AAC.47.5.1589-1597.2003.
102. LaPlante KL. 2007. In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 57:413-418. http://dx.doi.org/10.1016/j.diagmicrobio.2006.09.007.
103. Milstone AM, Passaretti CL, Perl TM. 2008. Chlorhexidine: expanding the armamentarium for infection control and prevention. Clin Infect Dis 46:274-281. http://dx.doi.org/10.1086/524736.
104. Maki DG, Ringer M, Alvarado CJ. 1991. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 338:339-343. http://dx.doi.org/10.1016/0140-6736(91)90479-9.
105. Marschall J, Mermel LA, Fakih M, Hadaway L, Kallen A, O’Grady NP, Pettis AM, Rupp ME, Sandora T, Maragakis LL, Yokoe DS. 2014. Strategies to prevent central line-associated bloodstream infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 35(Suppl 2):S89-S107.
106. Vernon MO, Hayden MK, Trick WE, Hayes RA, Blom DW, Weinstein RA. 2006. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 166:306-312. http://dx.doi.org/10.1001/archinte.166.3.306.
107. Bleasdale SC, Trick WE, Gonzalez IM, Lyles RD, Hayden MK, Weinstein RA. 2007. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 167:2073-2079. http://dx.doi.org/10.1001 /archinte.167.19.2073.
108. Borer A, Gilad J, Porat N, Megrelesvilli R, Saidel-Odes L, Peled N, Eskira S, Schlaeffer F, Almog Y. 2007. Impact of 4% chlorhexidine whole-body washing on multidrug-resistant Acinetobacter baumannii skin colonisation among patients in a medical intensive care unit. J Hosp Infect 67:149-155. http://dx.doi.org/10.1016/j.jhin.2007.07.023.
109. Milstone AM, Elward A, Song X, Zerr DM, Orscheln R, Speck K, Obeng D, Reich NG, Coffin SE, Perl TM. 2013. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. Lancet 381:1099-1106. http://dx.doi.org/10.1016/S0140-6736(12)61687-0.
110. Derde LP, Cooper BS, Goossens H, Malhotra-Kumar S, Willems RJ, Gniadkowski M, Hryniewicz W, Empel J, Dautzenberg MJ, Annane D, Aragao I, Chalfine A, Dumpis U, Esteves F, Giamarellou H, Muzlovic I, Nardi G, Petrikkos GL, Tomic V, Marti AT, Stammet P, Brun- Buisson C, Bonten MJ. 2014. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis 14:31-39. http://dx.doi.org/10.1016/S1473-3099(13)70295-0
111. Noto MJ, Domenico HJ, Byrne DW, Talbot T, Rice TW, Bernard GR, Wheeler AP. 2015. Chlorhexidine bathing and health care-associated infections: a randomized clinical trial. JAMA 313:369-378. http://dx.doi.org/10.1001/jama.2014.18400.
112. Lin MY, Lolans K, Blom DW, Lyles RD, Weiner S, Poluru KB, Moore N, Hines DW, Weinstein RA, Hayden MK. 2014. The effectiveness of routine daily chlorhexidine gluconate bathing in reducing Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae skin burden among long-term acute care hospital patients. Infect Control Hosp Epidemiol 35:440-442. http://dx.doi.org/10.1086/675613.
113. Hayden MK, Lin MY, Lolans K, Weiner S, Blom D, Moore NM, Fogg L, Henry D, Lyles R, Thurlow C, Sikka M, Hines D, Weinstein RA. 2015. Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long-term acute-care hospitals. Clin Infect Dis 60:1153-1161. http://dx.doi.org/10.1093/cid /ciu1173.
114. Cassir N, Thomas G, Hraiech S, Brunet J, Fournier PE, La Scola B, Papazian L. 2015. Chlorhexidine daily bathing: impact on health care associated infections caused by gram-negative bacteria. Am J Infect Control 43:640-643. http://dx.doi.org/10.1016/j.ajic.2015.02.010.
115. Rupp ME, Cavalieri RJ, Lyden E, Kucera J, Martin M, Fitzgerald T, Tyner K, Anderson JR, VanSchooneveld TC. 2012. Effect of hospital-wide chlorhexidine patient bathing on healthcare-associated infections. Infect Control Hosp Epidemiol 33:1094 -1100. http://dx.doi.org/10.1086/668024.
116. Edmiston CE, Jr, Krepel CJ, Seabrook GR, Lewis BD, Brown KR, Towne JB. 2008. Preoperative shower revisited: can high topical antiseptic levels be achieved on the skin surface before surgical admission? J Am Coll Surg 207: 233-239. http://dx.doi.org/10.1016/j.jamcollsurg.2007.12.054.
117. Supple L, Kumaraswami M, Kundrapu S, Sunkesula V, Cadnum JL, Nerandzic MM, Tomas M, Donskey CJ. 2015. Chlorhexidine only works if applied correctly: use of a simple colorimetric assay to provide monitoring and feedback on effectiveness of chlorhexidine application. Infect Control Hosp Epidemiol 36:1095-1097. http://dx.doi.org/10.1017 /ice.2015.124.
118. Frederick JJ, Corner TR, Gerhardt P. 1974. Antimicrobial actions of hexa-chlorophene: inhibition of respiration in Bacillus megaterium. Antimicrob Agents Chemother 6:712-721. http://dx.doi.org/10.1128/AAC.6.6.712
119. Sanofi-Synthelabo Inc. 2003. Phisohex (hexachlorophane) package insert. Sanofi-Synthelabo Inc., New York, NY.
120. Block C, Robenshtok E, Simhon A, Shapiro M. 2000. Evaluation of chlorhexidine and povidone iodine activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis using a surface test. J Hosp Infect 46:147-152. http://dx.doi.org/10.1053 /jhin.2000.0805.
121. Smylie HG, Logie JR, Smith G. 1973. From Phisohex to Hibiscrub. Br Med J 4:586-589. http://dx.doi.org/10.1136/bmj.4.5892.586.
122. Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. 2002. Chlorhexi dine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med 136:792-801. http://dx.doi.org/10.7326/0003-4819-136-11-200206040-00007.
123. Al-Doori Z, Morrison D, Edwards G, Gemmell C. 2003. Susceptibility of MRSA to triclosan. J Antimicrob Chemother 51:185-186. http://dx.doi.org/10.1093/jac/dkg013.
124. Giuliano CA, Rybak MJ. 2015. Efficacy of triclosan as an antimicrobial hand soap and its potential impact on antimicrobial resistance: a focused review. Pharmacotherapy 35:328-336. http://dx.doi.org/10.1002/phar.1553.
125. Fritz SA, Camins BC, Eisenstein KA, Fritz JM, Epplin EK, Burnham CA, Dukes J, Storch GA. 2011. Effectiveness of measures to eradicate Staphylococcus aureus carriage in patients with community-associated skin and soft-tissue infections: a randomized trial. Infect Control Hosp Epidemiol 32:872-880. http://dx.doi.org/10.1086/661285.
126. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52:285-292. http://dx.doi.org/10.1093/cid/cir034
127. Chlebicki MP, Safdar N. 2007. Topical chlorhexidine for prevention of ventilator-associated pneumonia: a meta-analysis. Crit Care Med 35: 595-602. http://dx.doi.org/10.1097/01.CCM.0000253395.70708.AC
128. Labeau SO, Van de Vyver K, Brusselaers N, Vogelaers D, Blot SI. 2011. Prevention of ventilator-associated pneumonia with oral antiseptics: a systematic review and meta-analysis. Lancet Infect Dis 11:845-854 http://dx.doi.org/10.1016/S1473-3099(11)70127-X.
129. Munro CL, Grap MJ, Jones DJ, McClish DK, Sessler CN. 2009. Chlorhexidine, toothbrushing, and preventing ventilator-associated pneumonia in critically ill adults. Am J Crit Care 18:428-437. (Quiz, 18:438.) http://dx.doi.org/10.4037/ajcc2009792.
130. Pineda LA, Saliba RG, El Solh AA. 2006. Effect of oral decontamination with chlorhexidine on the incidence of nosocomial pneumonia: a meta analysis. Crit Care (London, England) 10:R35. http://dx.doi.org/10.1186 /cc4837.
131. DeRiso AJ, II, Ladowski JS, Dillon TA, Justice JW, Peterson AC. 1996. Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. Chest 109:1556-1561. http://dx.doi.org/10.1378/chest.109.6.1556.
132. Houston S, Hougland P, Anderson JJ, LaRocco M, Kennedy V, Gentry LO. 2002. Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery. Am J Crit Care 11:567-570.
133. Klompas M, Speck K, Howell MD, Greene LR, Berenholtz SM. 2014. Reappraisal of routine oral care with chlorhexidine gluconate for patients receiving mechanical ventilation: systematic review and meta-analysis. JAMA Intern Med 174:751-761. http://dx.doi.org/10.1001/jamainternmed.2014.359.
134. Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, Montgomerie JZ, Goetz MB, Mayhall CG, Rimland D, et al. 1993. Randomized double-blinded trial of rifampin with either novobiocin or imethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 37: 1334-1342. http://dx.doi.org/10.1128/AAC.37.6.1334.
135. Simor AE, Phillips E, McGeer A, Konvalinka A, Loeb M, Devlin HR, Kiss A. 2007. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 44:178-185. http://dx.doi.org/10.1086 /510392.
136. Cluzet VC, Gerber JS, Nachamkin I, Metlay JP, Zaoutis TE, Davis MF, Julian KG, Royer D, Linkin DR, Coffin SE, Margolis DJ, Hollander JE, Mistry RD, Gavin LJ, Tolomeo P, Wise JA, Wheeler MK, Bilker WB, Han X, Hu B, Fishman NO, Lautenbach E. 2015. Duration of colonization and determinants of earlier clearance of colonization with meth- icillin-resistant Staphylococcus aureus. Clin Infect Dis 60:1489-1496. http://dx.doi.org/10.1093/cid/civ075.
137. Muder RR, Boldin M, Brennen C, Hsieh M, Vickers RM, Mitchum K, Yee YC. 1994. A controlled trial of rifampicin, minocycline, and rifampicin plus minocycline for eradication of methicillin-resistant Staphylococcus aureus in long-term care patients. J Antimicrob Chemother 34: 189-190. http://dx.doi.org/10.1093/jac/34.1.189.
138. D’Amico R, Pifferi S, Leonetti C, Torri V, Tinazzi A, Liberati A. 1998. Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials. BMJ 316:1275-1285.
139. Chan EY, Ruest A, Meade MO, Cook DJ. 2007. Oral decontamination for prevention of pneumonia in mechanically ventilated adults: systematic review and meta-analysis. BMJ 334:889. http://dx.doi.org/10.1136 /bmj.39136.528160.BE.
140. de Smet AM, Kluytmans JA, Cooper BS, Mascini EM, Benus RF, vander Werf TS, van der Hoeven JG, Pickkers P, Bogaers-Hofman D, van der Meer NJ, Bernards AT, Kuijper EJ, Joore JC, Leverstein-van Hall MA, Bindels AJ, Jansz AR, Wesselink RM, de Jongh BM, Dennesen PJ, van Asselt GJ, te Velde LF, Frenay IH, Kaasjager K, Bosch FH, van Iterson M, Thijsen SF, Kluge GH, Pauw W, de Vries JW, Kaan JA, Arends JP, Aarts LP, Sturm PD, Harinck HI, Voss A, Uijtendaal EV, Blok HE, Thieme Groen ES, Pouw ME, Kalkman CJ, Bonten MJ. 2009. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 360:20-31. http://dx.doi.org/10.1056/NEJMoa0800394
141. de Smet AM, Kluytmans JA, Blok HE, Mascini EM, Benus RF, Bernards AT, Kuijper EJ, Leverstein-van Hall MA, Jansz AR, de Jongh BM, van Asselt GJ, Frenay IH, Thijsen SF, Conijn SN, Kaan JA, Arends JP, Sturm PD, Bootsma MC, Bonten MJ. 2011. Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label, clus- tered group-randomised, crossover study. Lancet Infect Dis 11:372-380. http://dx.doi.org/10.1016/S1473-3099(11)70035-4.
142. Oostdijk EA, Kesecioglu J, Schultz MJ, Visser CE, de Jonge E, van Essen EH, Bernards AT, Purmer I, Brimicombe R, Bergmans D, van Tiel F, Bosch FH, Mascini E, van Griethuysen A, Bindels A, Jansz A, van Steveninck FA, van der Zwet WC, Fijen JW, Thijsen S, de Jong R, Oudbier J, Raben A, van der Vorm E, Koeman M, Rothbarth P, Rijkeboer A, Gruteke P, Hart-Sweet H, Peerbooms P, Winsser LJ, van Elsacker-Niele AM, Demmendaal K, Brandenburg A, de Smet AM, Bonten MJ. 2014. Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial. JAMA 312:1429-1437. http://dx.doi.org/10.1001/jama.2014.7247
143. Price R, MacLennan G, Glen J. 2014. Selective digestive or oropharyn-geal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis. BMJ 348:g2197. http://dx.doi.org/10.1136/bmj.g2197
144. Daneman N, Sarwar S, Fowler RA, Cuthbertson BH. 2013. Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Lancet Infect Dis 13:328-341. http://dx.doi.org/10.1016/S1473-3099(12)70322-5.
145. Huttner B, Haustein T, Uckay I, Renzi G, Stewardson A, Schaerrer D, Agostinho A, Andremont A, Schrenzel J, Pittet D, Harbarth S. 2013. Decolonization of intestinal carriage of extended-spectrum betalactamase-producing Enterobacteriaceae with oral colistin and neomycin: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother 68:2375-2382. http://dx.doi.org/10.1093/jac/dkt174.
146. Saidel-Odes L, Polachek H, Peled N, Riesenberg K, Schlaeffer F, Trabelsi Y, Eskira S, Yousef B, Smolykov R, Codish S, Borer A. 2012. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol 33:14-19. http://dx.doi.org/10.1086 /663206.
147. Oren I, Sprecher H, Finkelstein R, Hadad S, Neuberger A, Hussein K, Raz-Pasteur A, Lavi N, Saad E, Henig I, Horowitz N, Avivi I, Benyamini N, Fineman R, Ofran Y, Haddad N, Rowe JM, Zuckerman T. 2013. Eradication of carbapenem-resistant Enterobacteriaceae gastroin-testinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial. Am J Infect Control 41:1167-1172. http://dx.doi.org/10.1016/j.ajic.2013.04.018.
148. Abad CL, Pulia MS, Safdar N. 2013. Does the nose know? An update on MRSA decolonization strategies. Curr Infect Dis Rep 15:455-464. http://dx.doi.org/10.1007/s11908-013-0364-y.
149. Bode LG, Kluytmans JA, Wertheim HF, Bogaers D, Vandenbroucke-Grauls CM, Roosendaal R, Troelstra A, Box AT, Voss A, van der TweelI, van Belkum A, Verbrugh HA, Vos MC. 2010. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 362: 9-17. http://dx.doi.org/10.1056/NEJMoa0808939
150. Segers P, Speekenbrink RG, Ubbink DT, van Ogtrop ML, de Mol BA. 2006. Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial. JAMA 296:2460-2466. http://dx.doi.org/10.1001/jama.296.20.2460.
151. Cimochowski GE, Harostock MD, Brown R, Bernardi M, Alonzo N, Coyle K. 2001. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Ann Thoracic Surg 71:1572-1578. http://dx.doi.org/10.1016/S0003-4975(01)02519-X
152. Schweizer ML, Chiang HY, Septimus E, Moody J, Braun B, Hafner J, Ward MA, Hickok J, Perencevich EN, Diekema DJ, Richards CL, Cavanaugh JE, Perlin JB, Herwaldt LA. 2015. Association of a bundled intervention with surgical site infections among patients undergoing cardiac, hip, or knee surgery. JAMA 313:2162-2171. http://dx.doi.org/10.1001/jama.2015.5387.
153. Braun BL, Herwaldt L, Schweizer M, Hafner JM, Moody J, Richards CL, Ward MA, Hickok J, Perencevich E, Septimus E. 2014. Development and implementation of a consensus algorithm to optimize preoperative antimicrobial prophylaxis and decrease gram-positive surgical site infections for cardiac and orthopedic procedures p 33-56. In Advances in the prevention and control of HAIs. Publication no. 14-0003 Agency for Healthcare Research and Quality, Rockville, MD.
154. Healy DG, Duignan E, Tolan M, Young VK, O’Connell B, McGovern E. 2011. Should cardiac surgery be delayed among carriers of methicillin-resistant Staphylococcus aureus to reduce methicillin-resistant Staphylococcus aureus-related morbidity by preoperative decolonisation? Eur J Cardio-Thoracic Surg 39:68-74. http://dx.doi.org/10.1016/j.ejcts.2010.05.043.
155. Anderson DJ, Podgorny K, Berrios-Torres SI, Bratzler DW, Dellinger EP, Greene L, Nyquist AC, Saiman L, Yokoe DS, Maragakis LL, Kaye KS. 2014. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 35:605-627. http: //dx.doi.org/10.1086/591064.
156. Murthy A, De Angelis G, Pittet D, Schrenzel J, Uckay I, Harbarth S. 2010. Cost-effectiveness of universal MRSA screening on admission to surgery. Clin Microbiol Infect 16:1747-1753. http://dx.doi.org/10.1111 /j.1469-0691.2010.03220.x.. Lee BY, Tsui BY, Bailey RR, Smith KJ, Muder RR, Lewis GJ, Harrison LH. 2009. Should vascular surgery patients be screened preoperatively for methicillin-resistant Staphylococcus aureus? Infect Control Hosp Epidemiol 30:1158-1165. http://dx.doi.org/10.1086/648087.
157. Clancy CJ, Bartsch SM, Nguyen MH, Stuckey DR, Shields RK, Lee BY. 2014. A computer simulation model of the cost-effectiveness of routine Staphylococcus aureus screening and decolonization among lung and heart-lung transplant recipients. Eur J Clin Microbiol Infect Dis 33: 1053-1061. http://dx.doi.org/10.1007/s10096-013-2046-y.
158. Lee BY, Wiringa AE, Bailey RR, Goyal V, Tsui B, Lewis GJ, Muder RR, Harrison LH. 2010. The economic effect of screening orthopedic surgery patients preoperatively for methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 31:1130-1138. http://dx.doi.org/10.1086/656591.
159. Courville XF, Tomek IM, Kirkland KB, Birhle M, Kantor SR, Finlayson SR. 2012. Cost-effectiveness of preoperative nasal mupirocin treatment in preventing surgical site infection in patients undergoing total hip and knee arthroplasty: a cost-effectiveness analysis. Infect Control Hosp Epidemiol 33:152-159. http://dx.doi.org/10.1086/663704.
160. Young LS, Winston LG. 2006. Preoperative use of mupirocin for the prevention of healthcare-associated Staphylococcus aureus infections: a cost-effectiveness analysis. Infect Control Hosp Epidemiol 27:1304-1312. http://dx.doi.org/10.1086/509837.
161. Lee BY, Wiringa AE, Mitgang EA, McGlone SM, Afriyie AN, Song Y, Beigi RH. 2011. Routine pre-cesarean Staphylococcus aureus screening and decolonization: a cost-effectiveness analysis. Am J Managed Care 17:693-700.
162. Lee BY, Song Y, McGlone SM, Bailey RR, Feura JM, Tai JH, Lewis GJ, Wiringa AE, Smith KJ, Muder RR, Harrison LH, Piraino B. 2011. The economic value of screening haemodialysis patients for methicillin-resistant Staphylococcus aureus in the USA. Clin Microbiol Infect 17: 1717-1726. http://dx.doi.org/10.1111/j.1469-0691.2011.03525.x.
163. Nelson RE, Samore MH, Smith KJ, Harbarth S, Rubin MA. 2010.
164. Cost-effectiveness of adding decolonization to a surveillance strategy of screening and isolation for methicillin-resistant Staphylococcus aureus carriers. Clin Microbiol Infect 16:1740-1746. http://dx.doi.org/10.1111 /j.1469-0691.2010.03324.x.
165. Gidengil CA, Gay C, Huang SS, Platt R, Yokoe D, Lee GM. 2015. Cost-effectiveness of strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in an intensive care unit. Infect Control Hosp Epidemiol 36:17-27. http://dx.doi.org/10.1017/ice.2014.12.
166. Bloom BS, Fendrick AM, Chernew ME, Patel P. 1996. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis. Am J Kidney Dis 27:687-694. http://dx.doi.org/10.1016/S0272-6386(96)90104-3.
167. Huang SS, Septimus E, Avery TR, Lee GM, Hickok J, Weinstein RA, Moody J, Hayden MK, Perlin JB, Platt R, Ray GT. 2014. Cost savings of universal decolonization to prevent intensive care unit infection: implications of the REDUCE MRSA trial. Infect Control Hosp Epidemiol 35(Suppl 3):S23-S31. http://dx.doi.org/10.1086/677819.
168. Ziakas PD, Zacharioudakis IM, Zervou FN, Mylonakis E. 2015. Methicillin-resistant Staphylococcus aureus prevention strategies in the ICU:a clinical decision analysis. Crit Care Med 43:382-393. http://dx.doi.org /10.1097/CCM.0000000000000711.
169. Patel PA, Schora DM, Peterson KE, Grayes A, Boehm S, Peterson LR. 2014. Performance of the Cepheid Xpert(R) SA Nasal Complete PCR assay compared to culture for detection of methicillin-sensitive and methicillin-resistant Staphylococcus aureus colonization. Diagn Microbiol Infect Dis 80:32-34. http://dx.doi.org/10.1016/j.diagmicrobio.2014.05.019.
170. Morris K, Wilson C, Wilcox MH. 2012. Evaluation of chromogenic meticillin-resistant Staphylococcus aureus media: sensitivity versus turn-around time. J Hosp Infect 81:20-24. http://dx.doi.org/10.1016/j.jhin.2012.02.003.
171. Jeyaratnam D, Whitty CJ, Phillips K, Liu D, Orezzi C, Ajoku U, French GL. 2008. Impact of rapid screening tests on acquisition of meticillin resistant Staphylococcus aureus: cluster randomised crossover trial. BMJ 336:927-930. http://dx.doi.org/10.1136/bmj.39525.579063.BE.
172. Irish D, Eltringham I, Teall A, Pickett H, Farelly H, Reith S, Woodford N, Cookson B. 1998. Control of an outbreak of an epidemic methicillin-resistant Staphylococcus aureus also resistant to mupirocin. J Hosp Infect 39:19-26. http://dx.doi.org/10.1016/S0195-6701(98)90239-0.
173. Lee AS, Macedo-Vinas M, Francois P, Renzi G, Schrenzel J, Vernaz N, Pittet D, Harbarth S. 2011. Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case-control study. Clin Infect Dis 52:1422-1430. http://dx.doi.org/10.1093/cid/cir233.
174. Batra R, Cooper BS, Whiteley C, Patel AK, Wyncoll D, Edgeworth JD. 2010. Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant Staphylococcus aureus in an intensive care unit. Clin Infect Dis 50:210-217. http://dx.doi.org/10.1086/648717.
175. Naparstek L, Carmeli Y, Chmelnitsky I, Banin E, Navon-Venezia S. 2012. Reduced susceptibility to chlorhexidine among extremely-drug-resistant strains of Klebsiella pneumoniae. J Hosp Infect 81:15-19. http: //dx.doi.org/10.1016/j.jhin.2012.02.007.
176. Harbarth S, Tuan Soh S, Horner C, Wilcox MH. 2014. Is reduced susceptibility to disinfectants and antiseptics a risk in healthcare settings? A point/counterpoint review. J Hosp Infect 87:194-202. http://dx.doi.org/10.1016/j.jhin.2014.04.012.